Business Wire

Eight Sleep Introduces Pod 3: The Latest Generation of Sleep Fitness Technology That Improves Sleep Quality by up to 32%

Share

Today, Eight Sleep, the world’s first sleep fitness company, introduced Pod 3, a new version of their award-winning sleep technology. Pod 3 features a new quad-core CPU as well as upgrades to its sensor system, powering more accurate biometric and health tracking with twice the number of sensors and 4000x greater resolution. The new sensor system achieves 99% heart rate sensing accuracy compared to clinical reference¹. Furthermore, clinical data have shown that the technology behind Pod 3 can improve sleep quality index by up to 32%², increase deep sleep by up to 34%³, and increase heart rate variability (HRV) by up to 19%³. The release of Pod 3 is part of Eight Sleep’s journey to transform an ordinary bed into an advanced health platform that fuels both recovery and performance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727005241/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eight Sleep Introduces Pod 3: The Latest Generation of Sleep Fitness Technology That Improves Sleep Quality by up to 32% (Photo: Business Wire)

“From the start, we set out to create the best systems in the world to power sleep optimization, and with the launch of Pod 3 we are taking a giant leap forward,” said Matteo Franceschetti, Co-founder and CEO of Eight Sleep. “Three years after the launch of the original Pod, it is rewarding to see how our innovations are improving people’s lives, with clinically validated results that prove better recovery night after night.”

Thermoregulating technology that improves sleep quality and increases HRV

The Pod’s Active Grid layer, which wraps around any mattress like a cover, continues to provide dynamic heating and cooling between 55℉ and 110℉ on each side of the bed. This allows members to maintain a comfortable temperature range during sleep, which has been clinically demonstrated to improve sleep quality index, time spent in deep sleep, as well as heart rate variability:

  • Increase deep sleep by up to 34%³: After just one week of sleeping on the Pod, individuals experienced a 10% average increase and a 34% maximum increase in deep sleep. Individuals that initially had below-average deep sleep duration had the largest increase in deep sleep after using the Pod. As deep sleep is crucial for several key bodily processes, including learning and memory, recovery from exercise, immunity, and metabolism, sleeping on the Pod can be highly beneficial for people struggling to get optimal amounts of deep sleep each night.
  • Improve clinical sleep quality by up to 32%²: The Pod has been shown to improve the sleep quality of individuals by up to 32% using standard clinical measurements. The average Pod user also experiences 34% higher daytime energy scores, 23% fewer sleep interruptions, and 44% faster sleep onset, compared to their baseline before sleeping on the Pod.
  • Increase heart rate variability (HRV) by up to 19%³: After one week of sleeping on the Pod, users show an average increase in their HRV by 6%. For one in three Eight Sleep users, HRV increases by at least 10%, and one in four users sees an HRV increase of at least 15%. Importantly, individuals with a below-average HRV experienced the largest increases in HRV after sleeping on the Pod with an average 9% increase and a 19% maximum increase. An increase in HRV indicates improved recovery, cardiovascular health, and cognitive performance.

While still maintaining the award-winning features of the Pod 2 Pro, the new Pod 3 includes enhanced technology and an improved user experience with the following enhancements:

A new quad-core CPU to increase the Pod’s computing power

A powerful new quad-core CPU significantly increases computing power in Pod 3 that allows for double the amount of sensors for tracking key biometrics such as heart rate, HRV, respiratory rate, sleep stages, and more. With a more robust hardware system, the Pod can now locally process more complex data and algorithms, critical for biometrics tracking during sleep. Additionally, the new hardware allows for future deep-learning-powered features to be pushed to users via frequent cloud updates.

Invisible Sensing design featuring twice the number of sensors and 4000x greater resolution in sleep and health tracking

Pod 3 includes a new Invisible Sensing design of its sensor pack to maximize comfort while providing more accurate measurements with double the amount of sensors and 4000x greater sensor resolution. Building on the previous generation’s excellent biometric accuracy³, Pod 3’s dual sensors enable a further 20% improvement in heart rate variability accuracy, as well as a maximum error of heart rate of less than 1 beat per minute compared to clinical reference.

Dual-band Wi-Fi chip with 5GHz compatibility for a wider connectivity range

A new, dual-band Wi-Fi chip in the Hub extends compatibility from 2.4GHz networks to 5GHz networks, as well as improves support for mesh networks. This update increases connection speed and Wi-Fi stability, allowing the Pod to find the best balance between long-range and high bandwidth connectivity, regardless of the layout of the user’s home.

The Eight Sleep app provides health insights and more with 8+

The powerful features of Pod 3 are managed from the Eight Sleep app which serves as a one-stop dashboard to view health and sleep metrics, adjust sleep preferences, and manage temperature settings. With an optional 8+ membership users can take their sleep to the next level. 8+ unlocks the full intelligence of the product, built utilizing insights from more than 90 million hours of sleep data. The features in the Eight Sleep App include:

  • Temperature Autopilot: Autopilot uses AI to adjust the user’s sleeping temperature in real-time based on their sleep history, past temperature preferences, bedroom temperature, local weather, and user feedback.
  • Health and Sleep Reports: A Sleep Fitness Report is available daily, and includes key health metrics such as heart rate, heart rate variability, sleep time, deep sleep, REM sleep, and respiratory rate.
  • Connection to third-party wearables: Users can link their favorite third-party fitness devices with the Eight Sleep app to understand how their daytime activities affect their sleep. Devices supported include Peloton, Oura, Garmin, Apple Health, Google Health, Fitbit, Trainingpeaks, Polar, and Zwift.
  • Behavioral Insights: 8+ offers powerful sleep and health insights, based on more than 90 million hours of sleep data, and creates personalized recommendations for each user with actionable suggestions to promote positive behavior change.
  • Content designed to help you sleep: 8+ members get access to a growing library of content including guided breathing, yoga, meditations, and more designed to help users fall asleep faster and wake up energized.

“Pod 3 is the next step for Eight Sleep to push the boundaries of what is possible for sleep technology that not only monitors your health, but also improves it. The new sensing and computing hardware in Pod 3 allows for more complex biometric algorithms to be deployed, giving our members the best and most innovative features for restorative and preventative health. This was all achieved while making the Pod even more comfortable with a new Invisible Sensing design,” says Dr. David He, Vice President of Research and Development at Eight Sleep.

Available today

The Eight Sleep Pod 3 is available to purchase online today. Pricing starts at $2,095 for a Full size, $2,195 for Queen, $2,395 for King and California King Pod 3 Cover. Priority upgrades are available for existing Eight Sleep members. Eight Sleep upholds its customer satisfaction, offering up to a 100-night trial and free returns. For more information about Pod 3, check out the video here and to purchase the Pod, visit eightsleep.com.

About Eight Sleep

Eight Sleep is the world's first sleep fitness company with a mission to fuel human potential through optimal sleep. Their hardware, software, and AI technologies power pro athletes and everyday high performers around the globe, including snowboarding sensation and Olympic Gold-Medalist Red Gerard, the world’s fittest man 2021 CrossFit Games Winner Justin Medeiros, and the 8X Formula One Champions, Mercedes-AMG PETRONAS Formula One Team. Eight Sleep was named one of Fast Company's Most Innovative Companies in 2019 & 2022. The company was also recognized two years in a row by TIME's “Best Inventions of the Year.” Eight Sleep is available for purchase in North America (the United States and Canada) and throughout the United Kingdom, Europe (Belgium, France, Germany, Italy, Netherlands, and Spain) and Australia via eightsleep.com.

References

  1. Eight Sleep Pod’s Heart Rate and Heart Rate Variability Accuracy
  2. Eight Sleep Pod Leads to Improved Sleep Quality
  3. HRV, HR & Deep Sleep Improvement

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stephen Simmons
Jack Taylor PR
eightsleep@jacktaylorpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in

You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release

Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc

CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release

Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale

Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release

In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha

FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release

Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye